no one at rovefeller or cold spring habir laboratory have explicated or applied the tevhnique for the treatment of the cause of causalgia described by ej rstner the lancet p106 jan 14 1978 involving only two antibiotics and two bacteria.
many at rockefeller are dimply drug company ....
consider the complexity of eating feces to save your life when you have a c diff clostidium infection
vancomycin happy hospitals such as south nassau communities hospital kill many
the wsj needs a more balanced and nuanced reporting
identification techniques for snaerobes have advanced but are still difficult
if you want to showup your faculty advisor at rockefeller ej ratner says you will find a previously unknown pathology in the maxillary sinuses of als patients. the sample may be obtsined from a living bring or a corpse. analyze it and you will explicate and be sble to treat the disease and no longer have to slave for the everything about nothing beings found at rockeller, the pharmaceutical farm
and yet the alfred e mirsky christmas lectures seem to have been delivered at rovkefeller by brighter minds of decent character?
note that the patient in the lancet supra was mrs j edward spike jr, the operation took place in boston, and her personal phydician was mark altschule of harvard
new york still foes not treat the cause of causalgia
Rockefeller University researchers led by biochemist Sean Brady (at right) extracted DNA directly out of soil samples. PHOTO: ZACH VEILLEUX/ROCKEFELLER UNIVERSITY
In a bag of backyard dirt, scientists have discovered a powerful new group of antibiotics they say can wipe out many infections in lab and animal tests, including some microbes that are resistant to most traditional antibiotics.
Researchers at Rockefeller University in New York reported the discovery of the new antibiotics, called malacidins, on Monday in the journal Nature Microbiology.
It is the latest in a series of promising antibiotics found through innovative genetic sequencing techniques that allow researchers to screen thousands of soil bacteria that previously could not be grown or studied in the laboratory. To identify the new compounds, the Rockefeller researchers sifted through genetic material culled from 1,500 soil samples.
“We extract DNA directly out of soil samples,” said biochemist Sean Brady at Rockefeller’s Laboratory for Genetically Encoded Small Molecules, a senior author on the new study. “We put it into a bug we can grow easily in the laboratory and see if it can make new molecules—the basis of new antibiotics.”
The new compounds appear to interfere with the ability of infectious bacteria to build cell walls—a function so basic to cellular life that it seems unlikely that the microbes could evolve a way to resist it. In lab tests, bacteria were exposed to the experimental antibiotics for 21 days without developing resistance, the scientists said.
So far, the new compounds also appear safe and effective in mice, but there are no plans yet to submit it for human testing. “It is early days for these compounds,” Dr. Brady said.
This image shows Enterobacteriaceae, a group of bacteria that includes common pathogens such as such as salmonella and shigella. PHOTO: U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION
The discovery of antibiotics in the early 20th century transformed modern medicine, but many of them gradually became ineffective as bacteria evolved defenses, often by acquiring protective genes from other more-resistant micro-organisms.
In the U.S. alone, at least two million illnesses and 23,000 deaths can be attributed each year to antibiotic-resistant bacteria, according to the U.S. Centers for Disease Control and Prevention. World-wide, deaths due to untreatable infections are predicted to rise 10-fold by 2050.
About 48 experimental antibioticsare undergoing clinical trials. Few of them, though, are aimed at the most intractable drug-resistant infections and, if past history is any guide, most are unlikely to be approved for patient use, several public-health experts said.
“Only a fraction of those will make it,” said Kathy Talkington, director of the Antibiotic Resistance Project at the Pew Charitable Trusts in Washington, D.C. “Generating new antibiotics and new therapies will take a while.”
In the quest for new antibiotics, researchers like Dr. Brady and others are deploying advanced genomics, synthetic-biology tools, and a variety of other innovative ways to explore a vast natural reservoir of bacteria notoriously difficult to isolate and study—the so-called “dark matter” of microbiology.
In May, researchers led by chemist Dale Boger at the Scripps Research Institute in San Diego created a more-potent version of vancomycin—considered an antibiotic of last resort for the most intractable infections. In a soil sample from Italy, researchers at Rutgers University last June unearthed a powerful new antibiotic called pseudouridimycin. Neither, though, is ready for clinical trials.
At Northeastern University in Boston, microbiologist Slava Epstein and his colleagues have screened thousands of bacteria strains using a portable device he invented called the iChip that allows bio-prospectors to isolate and grow finicky micro-organisms.
Researchers created an online citizen science project called ‘Drugs from Dirt’ that solicits donations of dirt from volunteers around the world. PHOTO: ROCKEFELLER UNIVERSITY
In 2016, they discovered an antibiotic called teixobactin. It too is years away from clinical trials.
“I did not understand how long it takes to develop an antibiotic, even when things go well,” he said.
To broaden their search for new therapeutic compounds, Dr. Brady and his Rockefeller colleagues set up an online citizen science project called “Drugs from Dirt” that solicits soil donations from around the world. The sandy soil that yielded the new malacidin antibiotics was shipped by relatives from the southwestern U.S.
“I think my parents sent it to me,” said Dr. Brady.
Write to Robert Lee Hotz at sciencejournal@wsj.com
